As of Oct 31, 2026, six DFW companies are being sold. Filings show what insiders get at five of them. The sixth is a $2.6B private sale, not in that total. Five should close by year-end. Range follows in early 2027.
Every number links to its source.
Range Resources
Natural gas producer. Paid in EQT stock, not cash.
Fort Worth, TX · Buyer: EQT · ~$55/share in EQT stock
$164.6Mto 10 insiders. Change-in-control pay plus shares owned.
Close: Q1 2027Signed Oct 25. No merger proxy yet. Both companies' shareholders must vote.
Top payouts
+7 more
Laith K. SandoSenior Vice President, Corporate Strategy
Brenda A. ClineDirector
Margaret K. DormanDirector
Christian S. KendallDirector
Reginal W. SpillerDirector
Deal team

Gibson, Dunn & CrutcherLawyers for Range Resources
Tull Florey source ↗
Jeffrey A. Chapman source ↗ 
Kirkland & EllisLawyers for the buyer David B. Feirstein source ↗Cyril V. Jones source ↗ 
EvercoreBankers for Range Resources filing ↗ 
J.P. Morgan SecuritiesBankers for Range Resources filing ↗ 
RBC Capital MarketsBankers for the buyer filing ↗
Filings
- No merger proxy yet, so these are not golden parachute figures. They come from Range's 2026 annual proxy and will change when the merger proxy is filed.
- Change-in-control figures are as of 2025-12-31 at $35.26 a share, well below the deal value. They are paid in full only if the person is let go. CEO Dennis Degner is set to join EQT's board.
- Shares owned are from the annual proxy (2026-03-16), less open-market sales and plus director grants on later Form 4s. They are valued here at $54.66 (0.987 x EQT's $55.38 close on 2026-10-30). The value moves with EQT stock.
- Unvested stock and performance units are not in the shares-owned figure. 2026 executive grants are left out, so executive totals are likely low.
- Alan Farquharson, a named executive in the proxy, is left out. The proxy says he planned to retire in June 2026.
8-K (merger agreement) · Oct 26, 2026 ↗ Press release · Oct 26, 2026 ↗ DEF 14A (change-in-control table, holdings) · Mar 31, 2026 ↗ 10-Q (subsequent event) · Oct 27, 2026 ↗
Integer Holdings
Plano, TX · Buyer: KKR · $127/share cash
$52.5Mto 20 insiders
Close: By year-endShareholders approved Oct 21. Awaiting regulators. Lawsuits filed.
Top payouts
Jim Stephens (LinkedIn)President, Cardiac Rhythm Management & Neuromodulation
+17 more
Andrew SennPresident, Cardio & Vascular
LB
Lindsay K. BlackwoodGeneral Counsel
JD
Joseph W. DziedzicFormer CEO
JH
John Harrisexecutive officer
TC
Tony Carrexecutive officer
KT
Kirk Thorexecutive officer
MM
Milo Metcalfexecutive officer
DS
Donald J. Spencenon-employee director
CM
M. Craig Maxwellnon-employee director
SA
Sheila Antrumnon-employee director
CC
Cheryl C. Cappsnon-employee director
MC
Michael J. Coylenon-employee director
JF
James Flanagannon-employee director
JH
James F. Hinrichsnon-employee director
AJ
Alvin (Tyrone) Jeffersnon-employee director
AK
Aaron Kapitonon-employee director
FP
Filippo Passerininon-employee director
Deal team

Davis Polk & WardwellLawyers for Integer Holdings
James P. Dougherty source ↗ 
Kirkland & EllisLawyers for the buyer Jennifer S. Perkins source ↗David M. Klein source ↗ 
Goldman SachsBankers for Integer Holdings filing ↗ 
Centerview, Barclays, Citi, Raymond JamesBankers for the buyer filing ↗
Filings
- Golden parachute figures assume closing on 2026-09-08 and a qualifying termination right after closing; cash severance is double-trigger. 'Other' = executive retention bonuses.
- If closing slips past 2027-01-15, ITGR may grant up to $23 million of 2027 RSUs that convert to cash, so actual amounts could rise.
- KKR's advisors per the deal press release: Centerview, Barclays, Citi and Raymond James. Lead arrangers: Citi, KKR Capital Markets, Barclays, UBS and Jefferies.
- Three shareholder suits seek to block the merger, plus 13 demand letters (8-K, 2026-10-14). KKR filed a Schedule 13D on 2026-10-13 reporting 4,753,677 shares.
8-K (1.01 merger agreement) · Aug 4, 2026 ↗ PREM14A · Sep 3, 2026 ↗ DEFM14A · Sep 14, 2026 ↗ 8-K (5.07 vote result) · Oct 21, 2026 ↗ 8-K (HSR early termination) · Sep 30, 2026 ↗
MapleMark Bank
Private Dallas bank. Paid in Scotiabank stock, not cash.
Dallas, TX · Buyer: Scotiabank · ~$11/share in Scotiabank stock
$49.1Mto 16 insiders. Shares owned plus change-in-control and retirement pay.
Close: Q4 2026Holders approve by written consent, no meeting. Bank regulators must clear it.
Top payouts
ED
Eric L. DavisPresident
+14 more
RL
Robert LangholzDirector
GS
Gerald Shaughnessy Sutton (LinkedIn)Chief Lending Officer
JM
John McNicholasDirector
EU
Ethan UnderwoodDirector
F
Five executivesChange-in-control and retirement pay, not split by person
Deal team

Norton Rose Fulbright USLawyers for MapleMark Bank Bryn A. Sappington source ↗Evan Hardee source ↗ 
Sullivan & CromwellLawyers for the buyer Stephen M. Salley source ↗ 
StephensBankers for MapleMark Bank James Clingman source ↗Pablo Vazquez source ↗
Filings
- $11.37 a share is the F-4's estimate, assuming $106.6M of closing equity. The real price is ($25M + closing equity) / all shares, paid in Scotiabank stock.
- Values are shares from the F-4 ownership table x $11.37, computed here. Options and warrants are left out, so these are slightly low.
- Change-in-control pay ($7,069,825) assumes a qualifying exit on 2026-12-01, and some of it depends on that. Retirement plan pay (about $5.0M) is the gross figure. The filing gives only totals.
- Director Boris Gutin (6.77%) is left out. His shares belong to GCP Capital funds.
F-4/A (Scotiabank) · Jul 24, 2026 ↗
Distribution Solutions
Owns Lawson Products, TestEquity, Gexpro Services
Fort Worth, TX · Buyer: LKCM Headwater (going private) · $35/share cash
$12.1Mto 9 insiders
Close: Q4 2026Final proxy filed Oct 28. Shareholders vote Nov 27.
Top payouts
+6 more
RC
Robert H. ConnorsCEO, Gexpro Services
SE
I. Steven EdelsonDirector
LH
Lee S. HillmanDirector
BR
Bianca A. RhodesDirector
RZ
Robert S. ZamarripaDirector
Deal team

McDermott Will & SchulteLawyers for Distribution Solutions Heidi J. Steele source ↗Eric Orsic source ↗ 
William Blair & CompanyBankers for Distribution Solutions filing ↗ 
J.P. Morgan SecuritiesBankers for the buyer filing ↗
Filings
- Insider-led take-private: LKCM (Fort Worth) already owns 78.5% and keeps it. The cash goes to the ~21.5% public float, not mainly to insiders.
- Golden parachute cash is severance on a qualifying termination (salary continuation), not triggered by the change in control itself.
- David Lambert (executive officer, options $287,130) and M. Bradley Wallace (director, no awards) omitted from payouts for lack of a golden-parachute or award amount beyond that line.
- Also filed 2026-09-01: PREM14A and Schedule 13E3 (going-private disclosure).
- Final proxy (DEFM14A) filed 2026-10-28 sets the special meeting for 2026-11-27. Its payout tables match the figures here.
8-K (1.01 merger agreement) · Jul 16, 2026 ↗ PRER14A (revised preliminary proxy) · Oct 20, 2026 ↗ DEFM14A (final proxy) · Oct 28, 2026 ↗
Sanara MedTech
Fort Worth, TX · Buyer: MiMedx · ~$35/share cash + stock
$9.5Mto 11 insiders
Close: Q4 2026, may slipShareholders approved Sep 30. FTC asked for more info Oct 15.
Top payouts
Jacob A. WaldropCOO
+8 more
RD
Robert A. DeSutterDirector
RM
Roszell Mack IIIDirector
ET
Eric D. TanzbergerDirector
SO
Sara N. OrtweinDirector
KM
Keith G. MyersDirector
RN
Ronald T. NixonFormer CEO
AB
Ann Beal SalamoneDirector
Deal team

Alston & BirdLawyers for Sanara MedTech filing ↗ 
Greenberg TraurigLawyers for the buyer filing ↗ 
Truist SecuritiesBankers for Sanara MedTech filing ↗ 
Centerview PartnersBankers for the buyer filing ↗
Filings
- Golden parachute figures assume closing 2026-11-01 and $35.00 per share. Cash includes retention bonus, severance and pro rata bonus.
- Close timing is at risk: the FTC Second Request (2026-10-15) means Q4 2026 may slip. No new date was stated.
- Muppalla (former Tissue Health Plus CEO) has $0 in the golden parachute table and is omitted.
- Nixon-affiliated entities hold 39% of shares (3,575,832; he has sole power over 64,042). His personal economic share is not disclosed. Part of the price is MiMedx stock, so it is not all cash.
- $35.00 is the value at signing ($33.00 cash + 0.4735 MiMedx share). The share ratio is fixed, so the value moves with MiMedx stock.
8-K (1.01 merger agreement) · Jul 29, 2026 ↗ DEFM14A (proxy statement/prospectus) · Sep 4, 2026 ↗ 8-K (5.07 vote result, HSR update) · Oct 1, 2026 ↗ 8-K (8.01 FTC Second Request) · Oct 16, 2026 ↗ DEF 14A (2026 annual proxy, share ownership) · Apr 17, 2026 ↗ DEF 14A (ownership footnotes) · Apr 17, 2026 ↗
Vaquero Midstream
Private Permian gas pipelines and plants.
Dallas, TX · Buyer: Energy Transfer · $1.95B cash + 33.3M units
$2.6Bsale price. Who gets what is not public.
Close: Q4 2026Announced Oct 6. Needs regulatory approval. No shareholder vote.
Who runs it
Harrison HolmesChief Executive Officer
Bryant Patton (LinkedIn)Chairman and Chief Financial Officer
Sandra Fendley (LinkedIn)Executive Vice President, Chief Accounting Officer
Deal team

Willkie Farr & GallagherLawyers for Vaquero Midstream
Jesse Betts source ↗
Jessica Hammons source ↗ 
Sidley AustinLawyers for the buyer George Vlahakos source ↗Atman Shukla source ↗ 
Houlihan LokeyBankers for Vaquero Midstream filing ↗ 
J.P. Morgan SecuritiesBankers for the buyer filing ↗
Filings
- Private company, so no SEC filing shows who gets what. The $2.625B is the sale price, not a payout to one person, and it is left out of the headline total.
- Sources are the advisers' announcements and press coverage, not SEC filings.
- Vaquero's investors include Yorktown Partners (New York) and Keeneland Capital, so much of the price likely goes to funds. Management's share is not disclosed.
Willkie announcement · Oct 6, 2026 ↗ Sidley announcement · Oct 6, 2026 ↗